pharmacoepidemiology

Eroglu, T. E., Coronel, R., & Souverein, P. C. (2024). Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study. Eur Heart J Cardiovasc Pharmacother. http://doi.org/10.1093/ehjcvp/pvae022
View
Shapiro, S. B., Yin, H., H. Y. Yu, O., & Azoulay, L. (2024). Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.16039
View
Pradhan, R., H. Y. Yu, O., Platt, R. W., & Azoulay, L. (2023). Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study. Bmj Open Diabetes Res Care, 11. http://doi.org/10.1136/bmjdrc-2023-003550
View
Jödicke, A. M., Tan, E. H., Robinson, D. E., Delmestri, A., & Prieto-Alhambra, D. (2023). Risk of adverse events following the initiation of antihypertensives in older people with complex health needs: a self-controlled case series in the United Kingdom. Age Ageing, 52. http://doi.org/10.1093/ageing/afad177
View
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., et al. (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
View
van Hulten, V., Driessen, J. H. M., Starup-Linde, J. K., Al-Mashhadi, Z. K., Viggers, R., Klungel, O. H., et al. (2023). The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab. http://doi.org/10.1111/dom.15220
View
Ashworth, J., Bajpai, R., Muller, S., Bailey, J., Helliwell, T., Harrisson, S. A., et al. (2023). Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study. The Lancet Regional Health - Europe, 27, 100579. http://doi.org/https://doi.org/10.1016/j.lanepe.2022.100579
View
Jani, M., Yimer, B. B., Selby, D., Lunt, M., Nenadic, G., & Dixon, W. G. (2023). "Take up to eight tablets per day": Incorporating free-text medication instructions into a transparent and reproducible process for preparing drug exposure data for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5595
View
Bidulka, P., Mathur, R., Lugo-Palacios, D. G., O'Neill, S., Basu, A., Silverwood, R. J., et al. (2022). Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study. Diabetes Obes Metab. http://doi.org/10.1111/dom.14874
View
Eroglu, T. E., Coronel, R., Zuurbier, C. J., Blom, M., de Boer, A., & Souverein, P. C. (2022). Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus. Eur Heart J Cardiovasc Pharmacother. http://doi.org/10.1093/ehjcvp/pvac043
View